Anavex shows data from certain Alzheimer’s disease drug trial
Anavex Life Sciences has reported pharmacokinetic (PK) and pharmacodynamic (PD) data for ANAVEX2-73 from its positive Phase 2a study in…
Pharmaceuticals, Biotechnology and Life Sciences
Anavex Life Sciences has reported pharmacokinetic (PK) and pharmacodynamic (PD) data for ANAVEX2-73 from its positive Phase 2a study in…
Anavex has ensured most of the cash for a U.S. multicentre Phase 2 clinical trial of Rett syndrome treatment Anavex2-73.
Anavex had cash and cash equivalents of $15.3 million as of September 30, 2015, compared with $7.3 million as at…
Anavex has appointed Ulrich Elben, PhD as Vice President of Preclinical Operations, who will be responsible for the pipeline development and optimization.
Kristina M. Capiak, CCRP has been promoted the Anavex Life Sciences Corp’s Vice President of Regulatory Affairs. She is overseeing U.S. and international regulatory matters for Anavex, including filings and interactions with the FDA and other regulatory authorities.
Anavex is moving forward with the development program for ANAVEX 2-73 for the treatment of Alzheimer’s disease in a…
Anavex has confirmed the information about positive safety and cognitive efficacy data from the Phase 2a Alzheimer’s trial for ANAVEX 2-73.
Anavex Life Sciences Corp., has announced it would be trading its common stock on the NASDAQ, an American/Canadian stock exchange, one…
Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS)…